Safety Study of BLS-M22 in Healthy Volunteers

Status Completed

Clinical Trial Summary

BLS-M22 is being developed as an anti-myostatin agent for the treatment of Duchenne Muscular Dystrophy (Muscular Dystrophy). A total of 37 subjects participated in this study to confirm the safety of BLS-M22.

Clinical Trial Description

This study is a dose Block-randomized, Double-blind, Placebo-controlled and Dose-escalation Phase I Clinical Trial to Evaluate Safety of BLS-M22. The single ascending dose group participated in 9 patients in each group(500mg, 1,000mg, 2000mg/BLS-M22 or Placebo(n=7:2)). The multiple ascending dose group participated in 10 patients(determined dose in SAD/BLS-M22 or Placebo(n=8:2)). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03789734
Study type	Interventional
Source	BioLeaders Corporation
Contact
Status	Completed
Phase	Phase 1
Start date	June 4, 2019
Completion date	November 27, 2020

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01865084` - A Study of Tadalafil for Duchenne Muscular Dystrophy	Phase 3
Completed	`NCT00243789` - Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy	Phase 1/Phase 2
Completed	`NCT00033189` - An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy	Phase 2
Completed	`NCT03703882` - Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy	Phase 3
Enrolling by invitation	`NCT04626674` - A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)	Phase 1
Completed	`NCT02286947` - Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy	Phase 2
Completed	`NCT03406780` - A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy	Phase 2
Completed	`NCT01826487` - Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)	Phase 3
Completed	`NCT02710591` - Rimeporide in Patients With Duchenne Muscular Dystrophy	Phase 1
Completed	`NCT01826422` - Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients	N/A
Completed	`NCT00102453` - Pentoxifylline in Duchenne Muscular Dystrophy	Phase 1/Phase 2
Terminated	`NCT02090959` - An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy	Phase 3
Recruiting	`NCT05833633` - Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations
Completed	`NCT05209087` - Effects of Parental Influence on Physical Activity Level and Participation in Children With Duchenne Muscular Dystrophy
Recruiting	`NCT05126758` - A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy	Phase 3
Completed	`NCT00016653` - Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy	Phase 2/Phase 3
Completed	`NCT03127241` - User-centred Assistive System for Arm Functions in Neuromuscular Subjects	N/A
Completed	`NCT03490214` - Non-invasive Imaging of Muscle Structure in Duchenne Muscular Dystrophy Using Multispectral Optoacoustic Tomography	N/A
Completed	`NCT03179631` - Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy	Phase 3
Terminated	`NCT03400852` - A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy	Phase 2